These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 37091854)

  • 1. Anoikis in phenotypic reprogramming of the prostate tumor microenvironment.
    Nepali PR; Kyprianou N
    Front Endocrinol (Lausanne); 2023; 14():1160267. PubMed ID: 37091854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis?
    Rennebeck G; Martelli M; Kyprianou N
    Cancer Res; 2005 Dec; 65(24):11230-5. PubMed ID: 16357123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell death under epithelial-mesenchymal transition control in prostate cancer therapeutic response.
    Begemann D; Anastos H; Kyprianou N
    Int J Urol; 2018 Apr; 25(4):318-326. PubMed ID: 29345000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Profiling Prostate Cancer Therapeutic Resistance.
    Wade CA; Kyprianou N
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting anoikis resistance in prostate cancer metastasis.
    Sakamoto S; Kyprianou N
    Mol Aspects Med; 2010 Apr; 31(2):205-14. PubMed ID: 20153362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anoikis and EMT: Lethal "Liaisons" during Cancer Progression.
    Cao Z; Livas T; Kyprianou N
    Crit Rev Oncog; 2016; 21(3-4):155-168. PubMed ID: 27915969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated Therapeutic Targeting of the Prostate Tumor Microenvironment.
    Livas L; Hasani S; Kyprianou N
    Adv Exp Med Biol; 2020; 1296():183-198. PubMed ID: 34185293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-Coding RNAs Set a New Phenotypic Frontier in Prostate Cancer Metastasis and Resistance.
    Altschuler J; Stockert JA; Kyprianou N
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoskeleton targeting value in prostate cancer treatment.
    Martin SK; Kamelgarn M; Kyprianou N
    Am J Clin Exp Urol; 2014; 2(1):15-26. PubMed ID: 25374905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AMPK/GSK3β/β-catenin cascade-triggered overexpression of CEMIP promotes migration and invasion in anoikis-resistant prostate cancer cells by enhancing metabolic reprogramming.
    Zhang P; Song Y; Sun Y; Li X; Chen L; Yang L; Xing Y
    FASEB J; 2018 Jul; 32(7):3924-3935. PubMed ID: 29505302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of BDNF/TrkB pathway promotes prostate cancer progression via induction of epithelial-mesenchymal transition and anoikis resistance.
    Li T; Yu Y; Song Y; Li X; Lan D; Zhang P; Xiao Y; Xing Y
    FASEB J; 2020 Jul; 34(7):9087-9101. PubMed ID: 32390303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anoikis molecular pathways and its role in cancer progression.
    Paoli P; Giannoni E; Chiarugi P
    Biochim Biophys Acta; 2013 Dec; 1833(12):3481-3498. PubMed ID: 23830918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting TUBB3 Suppresses Anoikis Resistance and Bone Metastasis in Prostate Cancer.
    Dong B; Gu Y; Sun X; Wang X; Zhou Y; Rong Z; Zhang J; Shi X; Zhang Z; He X; Chen L; Xiong Q; Pang X; Cui Y
    Adv Healthc Mater; 2024 Nov; 13(28):e2400673. PubMed ID: 38809199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance.
    Archer M; Dogra N; Kyprianou N
    Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33076397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging therapeutics targeting castration-resistant prostate cancer: the AR-mageddon of tumor epithelial-mesenchymal transition.
    Hendrix LN; Hamilton DA; Kyprianou N
    Expert Rev Endocrinol Metab; 2013 Jul; 8(4):403-416. PubMed ID: 30736155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tetraiodothyroacetic acid and transthyretin silencing inhibit pro-metastatic effect of L-thyroxin in anoikis-resistant prostate cancer cells through regulation of MAPK/ERK pathway.
    Zhang P; Chen L; Song Y; Li X; Sun Y; Xiao Y; Xing Y
    Exp Cell Res; 2016 Oct; 347(2):350-9. PubMed ID: 27569004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Mechanism of prostate cancer invasion and metastasis].
    Sakamoto S; Ichikawa T
    Nihon Rinsho; 2014 Dec; 72(12):2086-9. PubMed ID: 25518338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
    Chung LW; Baseman A; Assikis V; Zhau HE
    J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer Stem Cells, Their Microenvironment and Anoikis.
    Ayla S; Karahüseyinogluc S
    Crit Rev Oncog; 2019; 24(1):27-34. PubMed ID: 31679217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redox regulation of anoikis resistance of metastatic prostate cancer cells: key role for Src and EGFR-mediated pro-survival signals.
    Giannoni E; Fiaschi T; Ramponi G; Chiarugi P
    Oncogene; 2009 May; 28(20):2074-86. PubMed ID: 19377510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.